Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
- 1 January 2018
- journal article
- research article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 3 (1) , 37-46
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Perspectives on The Design of Clinical Trials Combining Transarterial Chemoembolization and Molecular Targeted TherapyLiver Cancer, 2012
- Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolizationCancer Treatment Reviews, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Dose-Finding Study of the Multitargeted Tyrosine Kinase Inhibitor SU6668 in Patients with Advanced MalignanciesClinical Cancer Research, 2005
- Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasionJournal of Hepatology, 2004
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002